Randomized trial · people
Teriparatide plus denosumab: 12.9% spine BMD gain at 24 months
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Over 2 years, adding denosumab to teriparatide gave larger spine and hip bone density gains than either drug alone, with most of the extra gain arriving in the first year.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 94
- Published
- 2014
- Journal
- J Clin Endocrinol Metab
What they tested
The team tested whether 24 months of teriparatide and denosumab given together would raise hip and spine bone density more than either drug on its own.
How the study was done
A randomized controlled trial in 94 postmenopausal women with osteoporosis, planned in advance as a continuation of the original DATA trial. Women got teriparatide (the 20 μg daily arm), denosumab (the 60 mg every 6 months arm), or both for 24 months.

What they found
At 24 months, lumbar spine BMD (bone mineral density, a scan-based measure of bone strength) rose 12.9% with the combination, compared with 9.5% on teriparatide alone and 8.3% on denosumab alone. Femoral neck BMD rose 6.8% with both drugs versus 2.8% and 4.1%, and total hip BMD rose 6.3% versus 2.0% and 3.2%. Spine and hip density kept climbing in all three groups during year 2, but the year 2 gains were similar across groups. Blood markers of bone turnover C-telopeptide and N-terminal propeptide of type 1 procollagen were suppressed to the same degree with denosumab alone and with the combination, while osteocalcin fell more with denosumab alone.
What it doesn’t show
This was a small trial that measured bone density and blood markers, not fractures, so it does not show whether the combination prevents more broken bones. It included only postmenopausal women with osteoporosis.
The paper
Leder et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014.
The compound
More studies on Teriparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)Meta-analysis · people · 2024
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Teriparatide: more bony union at 6 months than zoledronate after PLIFRandomized trial · people · 2022
- Teriparatide: 45.4% of jaw osteonecrosis lesions resolved by 52 weeksRandomized trial · people · 2020
- Teriparatide: fewer new vertebral fractures than risedronate in VERORandomized trial · people · 2018
- Every study on Teriparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.